Compositions and methods for modulating the immune system

ABSTRACT

A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a T H 2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators therefore may have diagnostic non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection.

CROSS REFERENCES TO RELATED APPLICATIONS

This application claims priority from U.S. Provisional Application No.60/765,399 entitled “Characterization of Preimplantation Factor 1(PIF-1): An Embryo-Derived Peptide with Immune Modulatory Properties”filed Feb. 3, 2006, U.S. Provisional Application No. 60/765,393 entitled“PIF-1: An Embryo-Derived Peptide Prevents Autoimmune DiseaseDevelopment in Preclinical Trials” filed Feb. 3, 2006, and U.S.Provisional Application No. 60/765,398 entitled “GVHD Therapy In CancerPatients Using PIF (Preimplantation Factor): A Non Toxic Embryo-DerivedImmunemodulatory Peptide” filed Feb. 3, 2006, the contents of which areincorporated herein by reference in their entirety. This applicationalso claims priority from U.S. Provisional Application No. [not yetassigned] entitled “PIF-1 Induced Effects on PBMC Genome Alone andFollowing Exposure to CD3MAB/CD28MAB” filed May 5, 2006. Thisapplication is also a continuation-in-part of U.S. application Ser. No.10/971,760 entitled “PIF-Peptides Biologic Activities, Site of Actionand the Antibody to Detect PIF” filed Oct. 22, 2004, and U.S.application Ser. No. 11/110,990 entitled “PIF Tetrapeptides” filed Apr.20, 2005, the contents of which are incorporated herein by reference intheir entireties.

BACKGROUND

Mammalian pregnancy is a unique physiological event in which thematernal immune system interacts with the fetus in a very efficientmanner, beneficial for both parties. Pregnancy is an immune paradox,displaying no graft vs. host or host vs. graft effect. The factorsinvolved in this phenomenon are not yet fully elucidated although theyhave been extensively studied. The novel embryo-derived factor,preimplantation factor (PIF-1), may cause immune tolerance of pregnancyby creating maternal recognition of pregnancy shortly afterfertilization. Synthetic PIF-1 replicated the native peptide's effectand exerted potent immune modulatory effects on activated PBMCproliferation and cytokine secretion, acting through novel sites on PBMCand having an effect which is distinct from known immune-suppressivedrugs.

There is evidence that several autoimmune diseases, including multiplesclerosis and rheumatoid arthritis, undergo remission during pregnancy,supporting the view that there are unique protective mechanismsoperative during that lime period. This is particularly remarkablebecause the host/mother is simultaneously being exposed to a semi- ortotal allograft (donor embryo) without adverse immune effects.

Allogeneic bone marrow transplantation (BMT) is a well-establishedtreatment for malignant and non-malignant hematological diseases, and isperformed in tens of thousands of patients each year. Mature donor Tcells within the stem cell graft are the main mediators of thebeneficial immune effects, but they arc also responsible for theinduction of graft-versus-host disease (GVHD), the major cause ofmorbidity and mortality in BMT patients. GVHD occurs when transplanteddonor-derived T cells recognize proteins expressed by recipientantigen-presenting cells. Consequently, this recognition induces donorT-cell activation, proliferation, arid differentiation, leading to acellular and inflammatory attack on recipient target tissues. Acute orchronic GVHD occurs within a 100-day period post-BMT that leads todermatitis, enteritis, and hepatitis. The treatment of GVHD continues tobe a challenge. To eliminate undesirable host-derived hematopoieticelements before BMT, patients have traditionally been treated withmyeloablative conditioning regimens involving high-dose chemotherapy andtotal-body radiation. Up until now, standard GVHD prophylaxis andtherapy uses immune suppressive drugs (steroids and Cyclosporin A), thatplace patients in danger of opportunistic infections and tumor relapse.Numerous agents have been evaluated for GVHD, unfortunately with pooroutcome. Ideally, prophylaxis of BMT patients by immune modulation wouldallow transplant acceptance, while maintaining the ability to protectagainst pathogens or cancer.

Type 1 (insulin-dependent) diabetes (TIDM) is caused by autoimmunedestruction of the insulin-producing pancreatic beta cells. TIDMetiology is multifactorial, complex, and involves a combination ofgenetic, environmental, and immunological influences. TIDM is aprogressive, asymptomatic decline in beta cell function untilhyperglycemia develops. Near total beta-cell destruction may not beuniversal, and therefore therapeutic measures that stop destruction andperhaps lead to organ recovery could bring to major advances in TIDMmanagement. TIDM prevention is currently suboptimal, and most currenttherapies aim at controlling glucose levels using insulin, or (rarely)by islet transplants. There are also attempts to initiate immunetherapies using (anti-CD3 antibodies, and anti-thymocyte globulin) whichaim to block the autoimmune cascade when combined withrepair/regeneration of beta cells (e.g., glulisine,glucagon-like-peptide-1 (GLP-1), extendin-4), and Dia-Pep277 withlimited success.

Multiple sclerosis (MS) is a progressive debilitating autoimmune diseaseof the central nervous system that has a complex etiology where geneticpredisposition may be coupled with early childhood viral exposure.Consequently, there is a gradual destruction of the myelin sheath thatcauses motor, autonomic, sensory dysfunction that may lead to paralysis.Current therapies are based on limiting the damage by using steroids andinterferon, Copaxone and monoclonal antibodies, with limited success. Anoptimal therapy would reverse the neural damage by blocking theautoimmune cascade while allowing for myelin sheath repair. Theexperimental autoimmune encephalitis (EAE) model is widely usedcurrently to examine experimental treatments for MS.

Ulcerative colitis (UC) and Crohn's disease (CD), the primaryconstituents of inflammatory bowel disease (IBD), are precipitated by acomplex interaction of environmental, genetic, and immunoregulatoryfactors. Higher rates of IBD are seen in northern, industrializedcountries. IBD's are chronic inflammatory disorders of thegastrointestinal tract. Although the etiology is incompletelyunderstood, initiation and aggravation of the inflammatory process seemto be due to a massive local mucosal immune response. Cytokine-mediatedimpairment of viability and metabolic function of epithelial cells hasbeen suggested as a possible early pathogenic event in the developmentof inflammatory bowel disease (IBD). Among several currently usedtherapies are azulphidine, steroids and in more serious casesAzathioprine, 6-mercaptopurine and methotrexate are appropriate. Whensteroids fail, cyclosporine A may utilized. IBD's involve both local andsystemic alteration of the immune system. In recent years severalstudies were carried out using peripheral immune cells as well colonicbiopsies to examine the direct effect of possible therapeutic agents onthe condition. Data indicates that the milieu of peripheral PBMC isaltered and agents that were found to be disease modifiers by in situtesting were considered suitable for clinical application.

It has been observed that PIF has immune modulatory properties and suchpeptides are useful in the prevention and/or treatment of variousimmune-mediated diseases, including, but not limited to, autoimmunedisorders. Compositions and methods for treating and/or preventingimmune-mediated disorders are provided herein.

SUMMARY

Embodiments of the present invention provide compounds havingimmune-modulating and/or anti-inflammatory activity, wherein compoundsof the invention include peptides and peptidomimetics. The inventionfurther provides methods of using immune-modulating and/oranti-inflammatory compounds of the invention.

Further embodiments of the present invention provide methods fortreating a disease characterized by an immune disorder or inflammatoryresponse by administering an amount of a PIF peptide or peptidomimeticsufficient to treat, inhibit, or ameliorate the disease. Such compoundsare useful for treating diseases characterized by an immune disorder orinflammatory response diseases, e.g., inflammation, arthritis,auto-immune diseases, collagen diseases, or allergy. For example, thesecompounds can be used to treat subjects, including mammals such ashumans, having or at risk of having inflammation, arthritis, auto-immunediseases, collagen diseases, or allergy.

Embodiments of the present invention relate to biological effectsinduced in vitro and/or in vivo by pre-implantation factor (PIF)peptides, peptidomimetics, and compounds derived from pre-implantationembryos that harbors in part, is identical to, or is homologous to theamino acid sequence of PIF peptides or to the scrambled amino acidsequence of PIF peptides. In particular, the present invention relatesto use of PIF peptides or peptidomimetics to effect changes on theimmune system of a patient. More specifically, the addition of PIFpeptides creates specific changes both in cellular immunity, as well asin a patient's secreted cytokine profile.

DESCRIPTION OF THE DRAWINGS

In part, other aspects, features, benefits and advantages of theembodiments of the present invention will be apparent with regard to thefollowing description, appended claims and accompanying drawings where:

FIG. 1. PIF prevents GVHD development following high burden BMT. Thenumber of GVHD+ and GVHD− mice at three and five weeks after BMT wereevaluated. The differences between control and both 0.1 and 1 mg/kg/dayPIF administered for two weeks PIF group and tested one week later weresignificant. Also, the 1 mg/kg/day PIF-treated group using an Alzet®pump at five weeks after BMT provided significant protection,X²:P≦0.001, P≦0.01 and P≦0.05, respectively.

FIG. 2. PIF-treated mice with a high BMT burden that develop GVHD have alower score at 30 days post transplant. At 30 days post-BMT, thedifference between the control and the 0.1 and 1 mg/kg/day treated PIFgroups using an Alzet® pump, are significant. t-test P≦0.04 and P≦0.04.. At 50 days, the effect was not significant.

FIG. 3. Short-term PIF administration to mice with high-burden BMT isassociated with long term survival. PIF 1-5 mg/kg/day for two weeks wasadministered using an Alzet® pump and the effect on long-term survivalwas compared to control. In the lower-dose PIF-treated group, 7/9 micesurvived vs. control 2/10, X², P<0.01. The survival of the higher-dosetreated group was slightly lower, 5/9.

FIG. 4. PIF treatment prevents diabetes development in NOD male mice,adoptive transfer model. Male mice were injected IV with 250 M spleencells derived from diabetic female NOD mice. PIF 0.83-2.73 mg/kg/day wasadministered using Alzet® pump for 28 days. This was followed by a40-day observation period. In low-dose PIF group, no mice developed DM,while in the high-dose group, one mouse became diabetic vs. 6/7 incontrols, P<0.001.

FIG. 5. PIF treatment reduces degree of paralysis in EAE, an acutemultiple sclerosis model. SJL mice 7-8 weeks were injected in the tailbase with 1:1 of 200 μg proteolytic protein peptide (PLP) together with200 μg CFA and IFA t(containing mycobacterium tuberculosis). On the sameday and two days later, mice were injected IP with 250 ng pertussistoxin. On the first day of the experiment, PIF-1 0.75 mg/kg/day wasadministered using a subcutaneously implanted Alzet® pump. Paralysisscores (0=non to 5=death) were compared. PIF therapy resulted in overalldecreased scores. PIF-1's effect was compared to a control group bydaily monitoring degree of paralysis, up to 40 days. Mann-Whitneynon-parametric test, P<0.003. In addition, the mean clinical score atday 40 was significantly lower in the PIF-treated group vs. control,P<0.05.

DETAILED DESCRIPTION

Before the present compositions and methods are described, it is to beunderstood that this invention is not limited to the particularmolecules, compositions, methodologies or protocols described, as thesemay vary. It is also to be understood that the terminology used in thedescription is for the purpose of describing the particular versions orembodiments only, and is not intended to limit the scope of the presentinvention which will be limited only by the appended claims.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meanings as commonly understood by one of ordinary skillin the art. Although any methods and materials similar or equivalent tothose described herein can be used in the practice or testing ofembodiments of the present invention, the preferred methods, devices,and materials are now described. All publications mentioned herein areincorporated by reference. Nothing herein is to be construed as anadmission that the invention is not entitled to antedate such disclosureby virtue of prior invention.

It must also be noted that as used herein and in the appended claims,the singular forms “a”, “an”, and “the” include plural reference unlessthe context clearly dictates otherwise. Thus, for example, reference to“a cell” is a reference to one or more cells and equivalents thereofknown to those skilled in the art, and so forth.

As used herein, the term “about” means plus or minus 10% of thenumerical value of the number with which it is being used. Therefore,about 50% means in the range of 45%-55%.

“Administering” when used in conjunction with a therapeutic means toadminister a therapeutic directly into or onto a target tissue or toadminister a therapeutic to a patient whereby the therapeutic positivelyimpacts the tissue to which it is targeted. Thus, as used herein, theterm “administering”, when used in conjunction with PIF, can include,but is not limited to, providing PIF peptide into or onto the targettissue; providing PIF peptide systemically to a patient by, e.g.,intravenous injection whereby the therapeutic reaches the target;providing PIF peptide in the form of the encoding sequence thereof tothe target (e.g., by so-called gene-therapy techniques). “Administering”a composition may be accomplished by parenteral, oral or topicaladministration.

As used herein, the terms “pharmaceutically acceptable”,“physiologically tolerable” and grammatical variations thereof, as theyrefer to compositions, carriers, diluents and reagents, are usedinterchangeably and represent that the materials are capable ofadministration upon a mammal without the production of undesirablephysiological effects such as nausea, dizziness, rash, or gastric upset.In a preferred embodiment, the therapeutic composition is notimmunogenic when administered to a subject for therapeutic purposes.

As used herein, the term “therapeutic” means an agent utilized to treat,combat, ameliorate, prevent or improve an unwanted condition or diseaseof a subject, in part, embodiments of the present, invention aredirected to treating, ameloriating, preventing or improving inflammationand/or an immune-mediate disorder, including auto-immune diseases.

A “therapeutically effective amount” or “effective amount” of acomposition is a predetermined amount calculated to achieve the desiredeffect, i.e., to effectively inhibit or reduce inflammation and/or animmune-mediated disease. Effective amounts of compounds of the presentinvention can objectively or subjectively reduce or decrease theseverity or frequency of symptoms associated with inflammation and orimmune-mediated disorders. The specific dose of a compound administeredaccording to this invention to obtain therapeutic and/or prophylacticeffects will, of course, be determined by the particular circumstancessurrounding the case, including, for example, the compound administered,the route of administration, and the condition being treated. Thecompounds are effective over a wide dosage range and, for example,dosages per day will normally fall within the range of from about 0.01mg/kg to about 10 mg/kg, more preferably about 0.1 mg/kg to about 1mg/kg. However, it will be understood that the effective amountadministered will be determined by the physician in the light of therelevant circumstances including the condition to be treated, the choiceof compound to be administered, and the chosen route of administration,and therefore the above dosage ranges are not intended to limit thescope of the invention in any way. A therapeutically effective amount ofcompound of this invention is typically an amount such that when it isadministered in a physiologically tolerable excipient composition, it issufficient to achieve an effective systemic concentration or localconcentration in the tissue.

The terms “treat,” “treated,” or “treating” as used herein refers toboth therapeutic treatment and prophylactic or preventative measures,wherein the object is to prevent or slow down (lessen) an undesiredphysiological condition, disorder or disease, or to obtain beneficial ordesired clinical results. For the purposes of this invention, beneficialor desired clinical results include, but are not limited to, alleviationof symptoms; diminishment of the extent of the condition, disorder ordisease; stabilization (i.e., not worsening) of the state of thecondition, disorder or disease; delay in onset or slowing of theprogression of the condition, disorder or disease; amelioration of thecondition, disorder or disease state; and remission (whether partial ortotal), whether detectable or undetectable, or enhancement orimprovement of the condition, disorder or disease. Treatment includeseliciting a clinically significant response without excessive levels ofside effects. Treatment also includes prolonging survival as compared toexpected survival if not receiving treatment.

“Disease” or “disorder” refers to an impairment of the normal functionof an organism. As used herein, a disease may be characterized by, e.g.,an immune disorder or an inflammatory response w a combination of theseconditions.

“Immune-modulating” refers to the ability of a compound of the presentinvention to alter (modulate) one or more aspects of the immune system.The immune system functions to protect the organism from infection andfrom foreign antigens by cellular and humoral mechanisms involvinglymphocytes, macrophages, and other antigen-presenting cells thatregulate each other by means of multiple cell-cell interactions and byelaborating soluble factors, including lymphokines and antibodies, thathave autocrine, paracrine, and endocrine effects on immune cells.

“Immune disorder” refers to abnormal functioning of the immune system.Immune disorders can be caused by deficient immune responses (e.g., HIV,AIDS) or overactive immune responses (e.g., allergy, auto-immunedisorders). Immune disorders can result in the uncontrolledproliferation of immune cells, uncontrolled response to foreign antigensor organisms leading to allergic or inflammatory diseases, aberrantimmune responses directed against host cells leading to auto-immuneorgan damage and dysfunction, or generalized suppression of the immuneresponse leading to severe and recurrent infections. Immune disorderrefers to disorders of the innate immune system (innate immunity) andthe adaptive immune system (adaptive immunity). Innate immunity refersto an early system of defense that depends on invariant receptorsrecognizing common features of pathogens. The innate immune systemprovides barriers and mechanisms to inhibit foreign substances, inparticular through the action of macrophages and neutrophils. Theinflammatory response is considered part of innate immunity. The innateimmune system is involved in initiating adaptive immune responses andremoving pathogens that have been targeted by an adaptive immuneresponse. However, innate immunity can be evaded or overcome by manypathogens, and does not lead to immunological memory. Adaptive immunityrefers to the ability to recognize pathogens specifically and to provideenhanced protection against reinfection due to immunological memorybased on clonal selection of lymphocytes bearing antigen-specificreceptors. A process of random recombination of variable receptor genesegments and the pairing of different variable chains generates apopulation of lymphocytes, each bearing a distinct receptor, forming arepertoire of receptors that can recognize virtually any antigen. If thereceptor on a lymphocyte is specific for a ubiquitous serf antigen, thecell is normally eliminated by encountering the antigen early in itsdevelopment. Adaptive immunity is normally initiated when an innateimmune response fails to eliminate a new infection, and antigen andactivated antigen-presenting cells are delivered to draining lymphoidtissues. When a recirculating lymphocyte encounters its specific foreignantigen in peripheral lymphoid tissues, it is induced to proliferate andits progeny then differentiate into effector cells that can eliminatethe infectious agent. A subset of these proliferating lymphocytesdifferentiate into memory cells, capable of responding rapidly to thesame pathogen if it is encountered again.

Immune disorders caused by an impaired or immunocompromised immunesystem can produce a deficient immune response that leaves the bodyvulnerable to various viral, bacterial, or fungal opportunisticinfections. Causes of immune deficiency can include various illnessessuch as viruses, chronic illness, or immune system illnesses. Diseasescharacterized by an impaired immune system include, but are not limitedto, HIV/AIDS and severe combined immunodeficiency syndrome (SCIDS).

Immune disorders caused by an excessive response by the immune system.This excessive response can be an excessive response to one or moreantigens on a pathogen, or to an antigen that would normally be ignoredby the immune system. Diseases characterized by an overactive immunesystem include, but are not limited to, arthritis, allergy, asthma,pollinosis, atopy, and auto-immune diseases.

“Arthritis” refers to inflammation of the joints that can be caused,inter alia, by wear and tear on joints, or auto-immune attack onconnective tissues, or exposure to an allergen, e.g., as inadjuvant-induced arthritis. Arthritis is often associated with, orinitiated by, deposition of antibody-antigen complexes in jointmembranes and activation of an inflammatory response. Sometimes theimmune response is initiated by cells rather than antibodies, where thecells can produce a deposit in the joint membrane.

“Allergy” refers to an immune reaction to a normally innocuousenvironmental antigen (allergen), resulting from the interaction of theantigen with antibodies or primed T cells generated by prior exposure tothe same antigen. Allergy is characterized by immune and inflammatoryaspects, as the allergic reaction is triggered by binding of the antigento antigen-specific IgE antibodies bound to a high-affinity IgE receptoron mast cells, which, leads to antigen-induced cross-linking of IgE onmast cell surfaces, causing the release of large amounts of inflammatorymediators such as histamine. Later events in the allergic responseinvolve leukotrienes, cytokines, and chemokines, which recruit andactivate eosinophils and basophils. The late phase of this response canevolve into chronic inflammation, characterized by the presence ofeffector T cells and eosinophils, which is most clearly seen in chronicallergic asthma.

“Asthma” refers to a chronic inflammatory disorder affecting thebronchial tubes, usually triggered or aggravated by allergens orcontaminants. Asthma is characterized by constriction of the bronchialtubes, producing symptoms including, but not limited to, cough,shortness of breath, wheezing, excess production of mucus, and chestconstriction

“Atopy” refers to the tendency to develop so-called “classic” allergicdiseases such as atopic dermatitis, allergic rhinitis (hay fever), andasthma, and is associated with a capacity to produce an immunoglobulin E(IgE) response to common allergens. Atopy is often characterized by skinallergies including but not limited to eczema, urticaria, and atopicdermatitis. Atopy can be caused or aggravated by inhaled allergens, foodallergens, and skin contact with allergens, but an atopic allergicreaction, may occur in areas of the body other than where contact withthe allergan occurred. A strong genetic (inherited) component of atop issuggested by the observation that the majority of atopic dermatitispatients have at least one relative who suffers from eczema, asthma, orhay fever.

“Pollinosis,” “hay fever,” or “allergic rhinitis,” are terms that referto an allergy characterized by sneezing, itchy and watery eyes, a runnynose and a burning sensation of the palate and throat. Others seasonal,pollinosis is usually caused by allergies to airborne substances such aspollen, and the disease can sometimes be aggravated in an individual byexposure to other allergens to which the individual is allergic.

“Auto-immune” refers to an adaptive immune response directed at selfantigens. “Auto-immune disease” refers to a condition wherein the immunesystem reacts to a “self” antigen that it would normally ignore, leadingto destruction of normal body tissues. Auto-immune disorders areconsidered to be caused, at least, in part, by a hypersensitivityreaction similar to allergies, because in both cases the immune systemreacts to a substance that it normally would ignore. Auto-immunedisorders include, but are not limited to, Hashimoto's thyroiditis,pernicious anemia, Addison's disease, type I (insulin dependent)diabetes, rheumatoid arthritis, systemic lupus erythematosus,dermatomyositis, Sjogren's syndrome, lupus erythematosus, multiplesclerosis, myasthenia gravis, Reiter's syndrome, and Grave's disease,alopecia areata, anklosing spondylitis, antiphospholipid syndrome,auto-immune hemolytic anemia, auto-immune hepatitis, auto-immune innerear disease, auto-immune lymphoproliferative syndrome (ALPS),auto-immune thrombocytopenic purpura (ATP), Behcet's disease, bullouspemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatiguesyndrome immune deficiency syndrome (CFIDS), chronic inflammatorydemyelinating polyneuropathy, cicatricial pemphigold, cold agglutinindisease, CREST syndrome, Crohn's disease, Dego's disease,dermatomyositis, dermatomyositis, discoid lupus, essential mixedcryoglobulinemia, fibromyalgia-fibromyositis, Guillain-Barre syndrome,idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura(ITP), IgA nephropathy, juvenile arthritis, Meniere's disease, mixedconnective tissue disease, pemphigus vulgaris, polyarteritis nodosa,polychondritis, polyglancular syndromes, polymyalgia rheumatica,polymyositis, primary agammaglobulinemia, primary biliary cirrhosis,psoriasis, Raynaud's phenomenon, rheumatic fever, sarcoidosis,scleroderma, stiff-man syndrome, Takayasu arteritis, temporalarteritis/giant cell arteritis, ulcerative colitis, uveitis, vasculitis,vitiligo, and Wegener's granulomatosis.

“Collagen disease” or “connective tissue disease” refers to a chronicinflammatory auto-immune disorder in which autoantibodies attackcollagen found throughout the body. Connective tissues are composed oftwo major structural protein molecules, collagen and elastin; incollagen disease, autoantibodies directed against collagen, will damageboth collagen and elastin due to the resulting inflammation. Collagendiseases include, but arc not limited to, lupus erythematosus, Sjogren'ssyndrome, scleroderma, dermatomyositis, and polyarteritis nodosa.Rheumatoid-collagen disease refers to a disorder affecting theconnective tissue, with “rheumatic” symptoms including muscle stiffness,soreness and pain in the joints and associated structures.

“Inflammatory response” or “inflammation” a general term for the localaccumulation of fluid, plasma proteins and white blood cells initiatedby physical injury, infection, or a local immune response. Inflammationis an aspect of many diseases and disorders, including but not limitedto diseases related to immune disorders, viral infection, arthritis,auto-immune diseases, collagen diseases, allergy, asthma, pollinosis,and atopy. Inflammation is characterized by rubor (redness), dolor(pain), calor (heat) and tumor (swelling), reflecting, changes in localblood vessels leading to increased local blood flow which causes heatand redness, migration of leukocytes into surrounding tissues(extravasation), and the exit of fluid and proteins from the blood andtheir local accumulation in the inflamed tissue, which results inswelling and pain, as well as the accumulation of plasma proteins thataid in host defense. These changes are initiated by cytokines producedby activated macrophages. Inflammation is often accompanied by loss offunction due to replacement of parenchymal tissue with damaged tissue(e.g., in damaged myocardium), reflexive disuse due to pain, andmechanical constraints on function, e.g., when a joint swells duringacute inflammation, or when scar tissue bridging an inflamed jointcontracts as it matures into a chronic inflammatory lesion.

“Anti-inflammatory” refers to the ability of a compound of the presentinvention to prevent or reduce the inflammatory response, or to sootheinflammation by reducing the symptoms of inflammation such as redness,pain, heat, or swelling.

Inflammatory responses can be triggered by injury, for example injury toskin, muscle, tendons, or nerves. Inflammatory responses can also betriggered as part of an immune response. Inflammatory responses can alsobe triggered by infection, where pathogen recognition and tissue damagecan initiate an inflammatory response at the site of infection.Generally, infections agents induce inflammatory responses by activatinginnate immunity. Inflammation combats infection by delivering additionaleffector molecules and cells to augment the killing of invadingmicroorganisms by the front-line macrophages, by providing a physicalbarrier preventing the spread of infection, and by promoting repair ofinjured tissue. “Inflammatory disorder” is sometimes used to refer tochronic inflammation due to any cause.

Diseases characterized by inflammation of the skin, often characterizedby skin rashes, include but are not limited to dermatitis, atopicdermatitis (eczema, atopy), contact dermatitis, dermatitisherpetiformis, generalized exfoliative dermatitis, seborrheicdermatitis, drug rashes, erythema multiforme, erythema nodosum,granuloma annulare, poison ivy, poison oak, toxic epidermal necrolysisand roseacae.

Inflammation triggered by various kinds of injuries to muscles, tendonsor nerves caused by repetitive movement of a part of the body aregenerally referred to as repetitive strain injury (RSI). Diseasescharacterized by inflammation triggered by RSI include, but are notlimited to, bursitis, carpal tunnel syndrome, Dupuytren's contracture,epicondylitis (e.g. “tennis elbow”), “ganglion” (inflammation in a cystthat has formed in a tendon sheath, usually occurring on the wrist)rotator cuff syndrome, tendinitis (e.g., inflammation of the Achillestendon), tenosynovitis, and “trigger finger” (inflammation of the tendonsheaths of fingers or thumb accompanied by tendon swelling).

It is understood that the terms “immune disorder” and “inflammatoryresponse” are not exclusive. It is understood that many immune disordersinclude acute (short term) or chronic (long term) inflammation. It isalso understood that inflammation can have immune aspects and non-immuneaspects. The role(s) of immune and nonimmune cells in a particularinflammatory response may vary with the type of inflammatory response,and may vary during the course of an inflammatory response. Immuneaspects of inflammation and diseases related to inflammation can involveboth innate and adaptive immunity. Certain diseases related toinflammation represent an interplay of immune and nonimmune cellinteractions, for example intestinal inflammation (Fiocchi et al., 1997Am J Physiol Gastrointest Liver Physiol 273: G769-G775), pneumonia (lunginflammation), or glomerulonephritis.

It is further understood that many diseases arc characterized by both animmune disorder and an inflammatory response, such that the use ofdiscrete terms “immune disorder” or “inflammatory response” is notintended to limit the scope of use or activity of the compounds of thepresent invention with respect to treating a particular disease. Forexample, arthritis is considered an immune disorder characterized byinflammation of joints, but arthritis is likewise considered aninflammatory disorder characterized by immune attack on joint tissues.Thus, the observation that a compound of the invention reduces theinflammation seen in an animal model of arthritis, does not limit theobserved activity of the compound to anti-inflammatory activity. In adisease having both immune and inflammatory aspects, merely measuringthe effects of a compound of the present invention of inflammation doesnot exclude the possibility that the compound may also haveimmune-modulating activity in the same disease. Likewise, in a diseasehaving both immune and inflammatory aspects, merely measuring theeffects of a compound of the present invention on immune responses doesnot exclude the possibility that the compound may also haveanti-inflammatory activity in the same disease.

As used herein, the terms “peptide”, “polypeptide” and “protein” areused interchangeably and refer to two or more amino acids covalentlylinked by an amide bond or non-amide equivalent. The peptides of theinvention can be of any length. For example, the peptides can have fromabout two to about 100 or more residues, such as, 5 to 12, 12 to 15, 15to 18, 18 to 25, 25 to 50, 50 to 75, 75 to 100, or more in length.Preferably, peptides are from about 2 to about 18 residues. The peptidesof the invention include 1- and d-isomers, and combinations of 1- andd-isomers. The peptides can include modifications typically associatedwith post-translational processing of proteins, for example, cyclization(e.g., disulfide or amide bond), phosphorylation, glycosylation,carboxylation, ubiquitination, myristylation, or lipidation.

Peptides disclosed herein further include compounds having amino acidstructural and functional analogues, for example, peptidomimetics havingsynthetic or non-natural amino acids or amino acid analogues, so long asthe mimetic has one or more functions or activities of compounds of theinvention. The compounds of the invention therefore include “mimetic”and “peptidomimetic” forms.

The terms “mimetic,” “peptide mimetic” and “peptidomimetic” are usedinterchangeably herein, and generally refer to a peptide, partialpeptide or non-peptide molecule that mimics the tertiary bindingstructure or activity of a selected native peptide or protein functionaldomain (e.g., binding motif or active site). These peptide mimeticsinclude recombinantly or chemically modified peptides, as well asnon-peptide agents such as small molecule drug mimetics, as furtherdescribed below.

In one embodiment, the PIF peptides of the invention are modified toproduce peptide mimetics by replacement of one or more naturallyoccurring side chains of the 20 genetically encoded amino acids (or Damino acids) with other side chains, for instance with groups such asalkyl, lower alkyl, cyclic 4, 5-, 6-, to 7 membered alkyl, amide, amidelower alkyl, amide di(lower alkyl), lower alkoxy, hydroxy, carboxy andthe lower ester derivatives thereof, and with 4-, 5-, 6-, to 7 memberedheterocyclics. For example, proline analogs can be made in which thering size of the proline residue is changed from 5 members to 4, 6, or 7members. Cyclic groups can be saturated or unsaturated, and ifunsaturated, can be aromatic or nonaromatic. Heterocyclic groups cancontain one or more nitrogen, oxygen, and/or sulphur heteroatoms.Examples of such groups include the furazanyl, furly, imidazolidinyl,imidazolyl, imidazolinyl, isothiazolyl, isoxazolyl, morpholinyl (e.g.morpholino), oxazolyl, piperazinyl (e.g. 1-piperazinyl), piperidyl (e.g.1-piperidyl, piperidino), pyranyl, pyrazinyl, pyrazolidinyl,pyrazolinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolidinyl(e.g. 1-pyrrolidinyl), pyrrolinyl, pyrrolyl, thiadiazolyl, thiazolyl,thienyl, thiomorpholinyl (e.g. thiomorpholino), and triazolyl. Theseheterocyclic groups can be substituted or unsubstituted. Where a groupis substituted, the substituent can be alkyl, alkoxy, halogen, oxygen,or substituted or unsubstituted phenyl. Peptidomimetics may also haveamino acid residues that have been chemically modified byphosphorylation, sulfonation, biotinylation, or the addition or removalof other moieties.

A variety of techniques are available for constructing peptide mimeticswith the same or similar desired biological activity as thecorresponding native but with more favorable activity than the peptidewith respect to solubility, stability, and/or susceptibility tohydrolysis or proteolysis (see. e.g., Morgan & Gainor, Ann. Rep. Med.Chem. 24,243-252,1989). Certain peptidomimetic compounds are based uponthe amino acid sequence of the peptides of the invention. Often,peptidomimetic compounds are synthetic compounds having athree-dimensional structure (i.e. a “peptide motif”) based upon thethree-dimensional structure of a selected peptide. The peptide motifprovides the peptidomimetic compound with the desired biologicalactivity, i.e., binding to PIF receptors, wherein the binding activityof the mimetic compound is not substantially reduced, and is often thesame as or greater than the activity of the native peptide on which themimetic is modeled. Peptidomimetic compounds can have additionalcharacteristics that enhance their therapeutic application, such asincreased cell permeability, greater affinity and/or avidity andprolonged biological half-life.

Peptidomimetic design strategies are readily available in the art (see,e.g., Ripka & Rich, Curr. Op. Chem. Biol. 2,441-452,1998; Hruby et al.,Curr. Op. Chem. Biol. 1,114-119,1997; Hruby & Balse, Curr.Med. Chem.9,945-970,2000. One class of peptidomimetics a backbone that ispartially or completely non-peptide, but mimics the peptide backboneatom-for atom and comprises side groups that likewise mimic thefunctionality of the side groups of the native amino acid, residues.Several types of chemical bonds, e.g., ester, thioester, thioamide,retroamide, reduced carbonyl dimethylene and ketomethylene bonds, areknown in the art to be generally useful substitutes for peptide bonds inthe construction of protease-resistant peptidomimetics. Another class ofpeptidomimetics comprises a small non-peptide molecule that binds toanother peptide or protein, but which is not necessarily a structuralmimetic of the native peptide. Yet another class of peptidomimetics hasarisen from combinatorial chemistry and the generation of massivechemical libraries. These generally comprise novel templates which,though structurally unrelated to the native peptide, possess necessaryfunctional groups positioned on a nonpeptide scaffold to serve as“topographical” mimetics of the original peptide (Ripka & Rich, 1998,supra).

The first natural PIF compound identified, termed nPIF-1₍₁₅₎ (SEQ ID NO:1), is a 15 amino acid peptide. A synthetic version of this peptide,sPIF-1₍₁₅₎ (SEQ ID NO: 13), showed activity that was similar to thenative peptide, nPIF-1₍₁₅₎ (SEQ ID NO; 1). This peptide is homologous toa small region of the Circumsporozoite protein, a malaria parasite. Thesecond PIF peptide, nPIF-2₍₁₃₎, (SEQ ID NO: 7), includes 13 amino acidsand shares homology with a short portion of a large protein namedthyroid and retinoic acid transcription co-repressor, which isidentified as a receptor-interacting factor, (SMRT); the syntheticversion is sPIF-2 (SEQ ID NO: 14). The third distinct peptide,nPIF-3₍₁₈₎ (SEQ ID NO: 10), consists of 18 amino acids and matches asmall portion of reverse transcriptase; the synthetic version of thispeptide sPIF-3₍₁₈₎ is (SEQ ID NO: 15). nPIF-4₍₉₎ (SEQ ID NO: 12) shareshomology with a small portion of reverse transcriptase.

A list of PIF peptides, both natural and synthetic, are provided belowin Table 1. Antibodies to various PIF peptides and scrambled PIFpeptides are also provided.

TABLE 1 PIF Peptides (SEQ ID NO) Peptide Amino Acid Sequence SEQ ID NO:1 nPIF-1₁₅ MVRIKPGSANKPSDD isolated native, matches region ofCircumsporozoite protein (Malaria) SEQ ID NO: 2 nPIF-1_((15-alter))MVRIKYGSYNNKPSD isolated native, matches region of Circumsporozoiteprotein (Malaria) SEQ ID NO: 3 nPIF-1₍₁₃₎ MVRIKPGSANKPS isolated native,matches region of Circumsporozoite protein (Malaria) SEQ ID NO: 4nPIF-1₍₉₎ MVRIKPGSA isolated native, matches region of Circumsporozoiteprotein (Malaria) SEQ ID NO: 5 scrPIF-1₁₅ GRVDPSNKSMPKDIA synthetic,scrambled amino acid sequence from region of Circumsporozoite proteinMalaria SEQ ID NO: 6 nPIF-2₍₁₀₎ SQAVQEHAST isolated native, matchesregion of human retinoid and thyroid hormone receptor-SMRT SEQ ID NO: 7nPIF-2₍₁₃₎ SQAVQEHASTNMG isolated native, matches region of humanretinoid and thyroid hormone receptor (SMRT) SEQ ID NO: 8 scrPIF-2₍₁₃₎EVAQHSQASTMNG synthetic, scrambled amino acid sequence from region ofhuman retinoid and thyroid hormone receptor SMRT SEQ ID NO: 9scrPIF-2₍₁₄₎ GQASSAQMNSTGVH SEQ ID NO: 10 nPIF-3₍₁₈₎ SGIVIYQYMDDRYVGSDLisolated native, matches region of Rev Trans SEQ ID NO: 11 Neg controlGMRELQRSANK synthetic, scrambled amino acid sequence for negPIF- fromregion of Circumsporozoite protein 1₍₁₅₎ Malaria SEQ ID NO: 12 nPIF-4₍₉₎VIIIAQYMD isolated native, matches region of Rev Trans antibody ofnative isolated nPIF-1₁₅ AbPIF-1₍₁₅₎ (SEQ ID NO: 13) sPIF-1₍₁₅₎MVRIKPGSANKPSDD synthetic, amino acid sequence from region ofCircumsporozoite protein Malaria (SEQ ID NO: 14) sPIF-2₍₁₃₎SQAVQEHASTNMG synthetic, amino acid sequence from of human retinoid andthyroid hormone receptor SMRT (SEQ ID NO: 15) sPIF-3₍₁₈₎SGIVIYQYMDDRYVGSDL synthetic, amino acid sequence from region ofCircumsporozoite protein Malaria (SEQ ID NO: 16) sPIF-1₍₉₎ MVRIKPGSAsynthetic, amino acid sequence from region of Circumsporozoite proteinMalaria antibody of native isolated nPIF-2₍₁₃₎ AbPIF-2₍₁₃₎ antibody ofnative isolated nPIF-3₍₁₈₎ AbPIF-3₍₁₈₎ (SEQ ID NO: 17) sPIF-4₍₉₎VIIIAQYMD synthetic SEQ ID NO: 18 sPIF-1₍₅₎ MVRIK synthetic SEQ ID NO:19 sPIF-1₍₄₎ PGSA synthetic n = native, s = synthetic, scr = scrambled,same AA, ( ) = number of AA, Ab = antibody

In one embodiment of the present invention, a PIF peptide is provided.Such PIF peptides may be useful for treating or amelioratingimmune-mediated disorders, such as autoimmune diseases.

In another embodiment, a pharmaceutical composition comprising a PIFpeptide is provided. In preferred embodiments, the pharmaceuticalcomposition comprises an effective amount of a PIF peptide.

In a another embodiment, a method of treating or presentingimmune-mediated disorders is provided. In a preferred embodiment, themethod comprises administering an effective amount of a PIF peptide to asubject in need thereof. The methods are particularly useful in treatingor preventing immune-mediated disorders, including, but not limited to,graft-versus-host disease type I diabetes , multiple sclerosis,ulcerative colitis, Crohn'disease, rheumatoid arthritis and the like.

In a further embodiment, a method for treating or preventingimmune-mediated disorders comprising administering an effective amountof a PIF peptide in combination with one or more iimmunotherapeuticdrugs to a subject in need thereof is provided. Such a combination mayenhance the effectiveness of the treatment of either component alone, ormay provide less side effects and/or enable a lower dose of eithercomponent.

The present data demonstrate that short-term exposure to PIF-1 at lowdoses is associated with a long-term protection against development ofautoimmune disorders of disparate origin. While not wishing to be boundby theory, based on the currently understood aspects of PIF-1'smechanism of action, the peptide appears to act independently of thetype of pathophysiological features of the autoimmune disease examinedaddressing them in an etiology-independent manner. This agrees with theproperties- of PIF-1 following examination of its effects on PBMC. PIF-1was found to have widespread modulatory effects on cellular immunology,as well as on cytokine production and secretion acting through specificinducible receptors present on subtypes of PBMC. PIF-1 appears to affectdisparate aspects of immunity since it responds to various mitogenchallenge, PHA CD3MAb, CD3MAb/CD28MAb, and MLR. PIF-1 exposure blocksactivated, but not basal, PBMC proliferation. In addition while therewas some bias towards T_(H)2. PIF-1 caused an increase in both T_(H)1and T_(H)2 cytokines following mitogen exposure. This may indicate thatPIF-1 helps to maintain the balance between the two immune modalities,not allowing either extreme inflammation or immune suppression. Byblocking actuated, but not basal, immunity the ability to respond to animmunogenic challenge such as pathogen exposure, and/or maternalrejection is well maintained. This may explain the significant efficacyobserved in the current mouse studies. Overall, PIF-1's mechanism ofaction is distinct from other currently used immune suppressive agents.

The three autoimmune models studied are quite distinct: BMT replicatesexposure of the model organism to foreign immune cells as would be thecase in GVHD; NOD replicates Type 1 diabetes induced by a specificattack on the pancreas by transplanted foreign T cells; and EAE modelsMS by stimulating a bacterial toxin and protein immunogen attack on thenervous tissue of the brain. However, all of the models arecharacterized by an induced immune response against the host organismand, consequently, to the autoimmune-induced destruction of vital organsand, ultimately, death. PIF-1 appears to successfully neutralize theinitiation of this cascade irrespective of the initiating insult. Thiscan be analogized to pregnancy, in which the embryo is tolerated by themother, but the mother remains able to respond adequately to pathogens.Pregnancy may also leave the mother less susceptible to autoimmunity andmalignancy, to some degree. Therefore, recreating an environment whereselect cells are tolerated while pathogens are attacked in anon-pregnancy setting may be the central mechanism of PIF-1's action inautoimmune model systems.

In all three models, efficacy was obtained in low doses, 0.1-1mg/kg/day. By contrast, somewhat lower efficacy is observed at higherdosing in two models (NOD 2.73 mg/kg/day and BMT 5 mg/kg/day). Thisagrees with in vitro data where maximal PIF-1 efficacy was found at 1-50nM concentrations, while higher doses were either less effective or noteffective at ail. This further suggests a receptor-dependent mechanismof action that is mostly responsive at a narrow range of concentrationsand otherwise may be down-regulated when concentrations are raisedbeyond optimal levels. These observations strongly indicate that PIFexerts this biphasic effect through physiological and notpharmacological mechanisms.

While the mechanism for the long-term protective effect of PIF-1 as seenin these autoimmune models is not clear, and without wishing to be boundby theory, it appears that PIF-1 initiates, following mitogen exposure,a time-dependent block of proliferation and leads to a cascade of T_(H)2cytokine secretion, some being secreted earlier while others, later.Such sequential effects may lead to a long-term modification of theimmune environment.

PIF-1 appears to act through putatively novel receptors that arepredominantly expressed on monocytes and macrophages. However, whenstimulated by mitogens, the expression of these receptors becomessignificant on T and B Cells but not NK cells. Differences in theexpression pattern of PIF-1 receptors may explain the differences in theresponse induced by PIF-1 seen in un-stimulated and stimulatedenvironments. In an un-stimulated environment, PIF-1 may only have a lowlevel of activity on T and B Cells. However, activation of the immunesystem in response to an immune system challenge may lead to theexpression of the PIF-1 receptors on T and B Cells initiating long termtolerance.

PIF-1's action appears to be independent of TCR, calcium-channels or PKCpathways, mechanisms through which most immunosuppressive agents act,and CD4+/CD25+ cells (T reg) cells that are of relevance in variousautoimmune diseases. On the other hand, PIF-1's action may involveNFAT-1 suppression.

In pregnancy, embryo viability is dependent on maternal tolerance of theembryo, but there is a clear time lag between embryo expulsion bymiscarriage and reduction of PIF levels in maternal circulation. Infact, PIF disappears from maternal circulation up to three weeks beforematernal human chorionic gonadotropin (hCG) levels dropped andmiscarriage ensues. Perhaps, a similar mechanism is involved inmaintaining tolerance, or protective effects against autoimmunity longterm, as is documented in the three model systems tested followingcessation of therapy.

In n preliminary study, the effect of PIF-1 administration using anAlzet® pump for 7 days alter mating on implantation rates in mice wasexamined. As expected, PIF-1 did not exert any adverse effects.Moreover, PIF-1 may have actually increased the rates of fetal survivalvs. control by day 13 of pregnancy, as documented at the time ofCeasarean section. This data combined with the additional six animaltrials provides a strong support for the lack of PIF-1 toxicity.

We also found that FITC-PIF-1 injected IV in mice accumulated in thespleen and was cleared from circulation into the kidney within minutes.This shows that PIF-1 specifically targets immune cells of the spleen invivo, and has a short half-life in circulation. The long term effect ofPIF administration may reflect a pharmacodynamic type of mechanism sincethe peptide has a short half-life, rather than a pharmacologic effectthat is produced while the drug is given and is dependent on the levelsof the drug in the circulation.

The observations that PIF-1 exerts long-term protection after short-termexposure in all three models tested raises the possibility that PIF-1therapy could be used for long-term management of patients withautoimmune diseases, perhaps initially using an insulin pump that couldreplicate the function of an Alzet® pump followed by periodic PIF-1administration, over a long term. Other devices capable of continuousand/or long term administration may also be useful. In addition, it maybe possible to develop an increased half-life, modified peptide (such asby PEGylation) and/or to use transdermal delivery system for long term,but minimally invasive use. Finally, due to PIF-1's simple structure andsmall size, in which shorter versions of the peptide are similarlyeffective (at least in vitro), oral delivery may become possible, whichcould transform PIF-1 into a convenient chronic therapy.

Ultimately, a novel embryo-derived peptide, PIF, creates a tolerogenicstate at low doses following short-term treatment leading to long-termprotection in several distinct severe autoimmune models. This effect isexerted without apparent toxicity.

For therapeutic treatment of the specified indications, a PIF peptidemay be administered as such, or can be compounded and formulated intopharmaceutical compositions in unit dosage form for parenteral,transdermal, rectal, nasal, local intravenous administration, or,preferably, oral administration. Such pharmaceutical compositions areprepared in a manner well known in the art and comprise at least oneactive PIF peptide associated with a pharmaceutically carrier. The term“active compound”, as used throughout this specification, refers to atleast one compound selected from compounds of the formulas orpharmaceutically acceptable salts thereof.

In such a composition, the active compound is known as “activeingredient.” In making the compositions, the active ingredient willusually be mixed with a carrier, or diluted by a carrier, or enclosedwithin a carrier that may be in the form of a capsule, sachet, paper orother container. When the carrier serves as a diluent, it may be asolid, semisolid, or liquid material that acts as a vehicle, excipientof medium for the active ingredient. Thus, the composition can be in theform of tablets, pills, powders, lozenges, sachets , cachets elixirs,emulsion, solutions, syrups, suspensions, soft and hard gelatincapsules, sterile injectable solutions, and sterile packaged powders.

Some examples of suitable carriers, excipients, and diluents includelactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia,calcium phosphate alginates, calcium salicate, microcrystallinecellulose, polyvinylpyrrolidone, cellulose, tragacanth, gelatin, syrup,methyl cellulose, methyl- and propylhydroxybenzoates, tale, magnesiumstearate, water, and mineral oil. The formulations can additionallyinclude lubricating agents, wetting agents, emulsifying and suspendingagents, preserving agents, sweetening agents or flavoring agents. Thecompositions may be formulated so as to provide quick, sustained, ordelayed release of the active ingredient after administration to thepatient by employing procedures well known in the art.

For oral administration, a compound can be admixed with carriers anddiluents, molded into tablets, or enclosed m gelatin capsules. Themixtures can alternatively be dissolved in liquids such as 10% aqueousglucose solution, isotonic saline, sterile water, or the like, andadministered intravenously or by injection.

The local delivery of inhibitory amounts of active compound for thetreatment of immune disorders can be by a variety of techniques thatadminister the compound at or near the targeted site. Examples of localdelivery techniques are not intended to be limiting but to beillustrative of the techniques available. Examples include localdelivery catheters, site specific carriers, implants, direct injection,or direct applications, such as topical application.

Local delivery by an implant describes the surgical placement of amatrix that contains the pharmaceutical agent into the affected site.The implanted matrix releases the pharmaceutical agent by diffusion,chemical reaction, or solvent activators.

For example, in some aspects, the invention is directed to apharmaceutical composition comprising a PIF peptide, and apharmaceutically acceptable carrier or diluent, or an effective amountof pharmaceutical composition comprising a PIF peptide.

The compounds of the present invention can be administered in theconventional manner by any route where they are active. Administrationcan be systemic, topical, or oral. For example, administration can be,but is not limited to, parenteral, subcutaneous, intravenous,intramuscular, intraperitoneal, transdermal, oral, buccal, ocularroutes, intravaginally, by inhalation, by depot injections, or byimplants. Thus, modes of administration for the compounds of the presentinvention (either alone or in combination with other pharmaceuticals)can be, but are not limited to, subligual, injectable (includingshort-acting, depot, implant and pellet forms injected subcutaneously orintramuscularly), or by use of vaginal creams, suppositories, pessaries,vaginal rings, rectal suppositories, intrauterine devices, andtransdermal forms such as patches and creams.

Specific modes of administration will depend on the indication. Theselection of the specific route of administration and the dose regimenis to be adjusted or titrated by the clinician according to methodsknown to the clinician in order to obtain the optimal clinical response.The amount of compound to be administered is that amount which istherapeutically effective. The dosage to be administered will depend onthe characteristics of the subject being treated, e.g., the particularmammal or human treated, age, weight, health, types of concurrenttreatment, if any, and frequency of treatments, and can be easilydetermined by one of skill in the art (e.g., by the clinician).

Pharmaceutical formulations containing the compounds of the presentinvention and a suitable carrier can be solid dosage forms whichinclude, but are not limited to, tablets, capsules, cachets, pellets,pills, powders and granules; topical dosage forms which include, but arenot limned to, solutions, powders, fluid emulsions, fluid suspensions,semi-solids, ointments, pastes, creams, gels and jellies, and foams; andparenteral dosage forms which include, but are not limited to,solutions, suspensions, emulsions, and dry powder; comprising aneffective amount of a polymer or copolymer of the present invention. Itis also known in the art that the active ingredients can be contained insuch formulations with pharmaceutically acceptable diluents, fillers,disintegrants, binders, lubricants, surfactants, hydrophobic vehicles,water soluble vehicles, emulsifiers, buffers, humectants, moisturizers,solubilizers, preservatives and the like. The means and methods foradministration are known in the art and an artisan can refer to variouspharmacologic references for guidance. For example, ModernPharmaceutics, Banker & Rhodes, Marcel Dekker, Inc. (1979); and Goodman& Gilman's The Pharmaceutical Basis of Therapeutics, 6th Edition,MacMillan Publishing Co., New York (1980) can be consulted.

The compounds of the present invention can be formulated for parenteraladministration by injection, e.g., by bolus injection or continuousinfusion. The compounds can be administered by continuous infusionsubcutaneously over a predetermined period of time. Formulations forinjection can be presented in unit dosage form, e.g., in ampoules or inmulti-dose containers, with an added preservative. The compositions cantake such forms as suspensions, solutions or emulsions in oily oraqueous vehicles, and can contain formulatory agents such as suspending,stabilizing and/or dispersing agents.

For oral administration, the compounds can be formulated readily bycombining these compounds with pharmaceutically acceptable carriers wellknown in the art. Such carriers enable the compounds of the invention tobe formulated as tablets, pills, dragees, capsules, liquids, gels,syrups, slurries, suspensions and the like, for oral ingestion by apatient to be treated. Pharmaceutical preparations for oral use can beobtained by adding a solid excipient, optionally grinding the resultingmixture, and processing the mixture of granules, alter adding suitableauxiliaries, if desired, to obtain tablets or dragee cores. Suitableexcipients include, but are not limited to, fillers such as sugars,including, but not limited to, lactose, sucrose, mannitol, and sorbitol;cellulose preparations such as, but not limited to, maize starch, wheatstarch, rice starch, potato starch, gelatin, gum tragecanth, methylcellulose, hydroxypropylmethyl-celllose, sodium carboxymethylcellulose,and polyvinylpyrrolidone (PVP). If desired, disintegrating agents can beadded, such as, but not limited to, the cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodiumalginate.

Dragee cores can be provided with suitable coatings. For this purpose,concentrated sugar solutions can be used, which can optionally containgum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethyleneglycol, and/or titanium dioxide, lacquer solutions, and suitable organicsolvents or solvent mixtures. Dyestuffs or pigments can be added to thetablets or dragee coatings for identification or to characterizedifferent combinations of active compound doses.

Pharmaceutical preparations which can be used orally include, but arenot limited to, push-fit capsules made of gelatin, as well as soft,scaled capsules made of gelatin and a plasticizer, such as glycerol orsorbitol. The push-fit capsules can contain the active ingredients inadmixture with filler such as, e.g., lactose, binders such as, e.g.,starches, and/or lubricants such as, e.g., talc or magnesium stearateand, optionally, stabilizers. In soft capsules, the active compounds canbe dissolved or suspended in suitable liquids, such as fatty oils,liquid paraffin, or liquid polyethylene glycols. In addition,stabilizers can be added. All formulations for oral administrationshould be in dosages suitable for such administration.

For buccal administration, the compositions can take the form of, e.g.,tablets or lozenges formulated in a conventional manner.

For administration by inhalation, the compounds for use according to thepresent invention are conveniently delivered in the form of an aerosolspray presentation from pressurized packs or a nebulizer, with the useof a suitable propellant, e.g., dichlorodifluoromethane,trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide orother suitable gas. In the case of a pressurized aerosol the dosage unitcan be determined by providing a valve to deliver a metered amount.Capsules and cartridges of, e.g., gelatin for use in an inhaler orinsufflator can be formulated containing a powder mix of the compoundand a suitable powder base such as lactose or starch.

The compounds of the present invention can also be formulated in rectalcompositions such as suppositories or retention enemas, e.g., containingconventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds ofthe present invention can also be formulated as a depot preparation.Such long acting formulations can be administered by implantation (forexample subcutaneously or intramuscularly) or by intramuscularinjection.

Depot injections can be administered at about 1 to about 6 months orlonger intervals. Thus, for example, the compounds can be formulatedwith suitable polymeric or hydrophobic materials (for example as anemulsion in an acceptable oil) or ion exchange resins, or as sparinglysoluble derivatives, for example, as a sparingly soluble salt.

In transdermal administration, the compounds of the present invention,for example, can be applied to a plaster, or can be applied bytransdermal, therapeutic systems that are consequently supplied to theorganism.

Pharmaceutical compositions of the compounds also can comprise suitablesolid or gel phase carriers or excipients. Examples of such carriers orexcipients include but are not limited to calcium carbonate, calciumphosphate, various sugars, starches, cellulose derivates, gelatin, andpolymers such as, e.g., polyethylene glycols.

The compounds of the present invention can also be administered incombination with other active ingredients, such as, for example,adjuvants, or other compatible drugs or compounds where such combinationis seen to be desirable or advantageous in achieving the desired effectsof the methods described herein.

This invention and embodiments illustrating the method and materialsused may be further understood by reference to the followingnon-limiting examples.

EXAMPLE 1

Peptide synthesis; Synthetic PIF-1₁₅ (MVRIKPGSANKPSDD) was obtained bysolid-phase peptide synthesis (Peptide Synthesizer, Applied Biosystems)employing Fmoc (9-fluorenylmethoxycarbonyl) chemistry. Finalpurification is carried out by reverse-phase HPLC and identity isverified by MALDI-TOF mass spectrometry and amino acid analysis andpurified to >95%, by HPLC, and documented by mass spectrometry(Biosynthesis, Texas).

Mice: C57BL/6(H-2b) male and female and (C57BL/6xBALB/c) F1 male, five-to six-week-old mice (GVHD studies) and seven- to eight-week old SJLmice (MS studies) were purchased from Harlan (Israel), and male andfemale seven- to eight-week-old NOD mice were obtained from JacksonLaboratories (Maine). All mice were maintained under conditions approvedby the Institutional Animal Care and Use Committee of the HebrewUniversity in Jerusalem in accordance with the national laws andregulations for protection of animals.

GvHD model: Recipients (C57BL/6xBALB/c) F1 mice received lethalwhole-body irradiation by a single dose of 1000 rad/dose and werereconstituted with 5-8×10⁶ C57BL/6 bone marrow (BM) cells and 10-20×10⁶spleen cells. BM from C57BL/6 donor mice was collected by flushing offemur, humerus and tibia into 10% FCS/PBS. BM mononuclear cells wereisolated from the interface after centrifugation on a Ficoll-Hipaquegradient. Spleens were crushed through 70 μm screens into 10% FCS/PBS.BM cells plus spleen cells were inoculated intravenously into whole-bodyirradiated mice one-day post radiation. PIF-1 therapy (0.1-1 mg/kg/day)was administered in three separate animal trials 5-10/group vs. controlby implanting under anesthesia an Alzet® pump in the dorsal subcutaneousregion at the day of transplant for one to two weeks providingcontinuous release of PIF-1. Evaluation of GvHD model animals wascarried out by examining body weight, skin lesions, animal survival, andhistological examination. Animal weight was examined every three daysfollowing BM transplantation, scoring for skin manifestations of GVHDwas carried out from day 12 post BMT up to four months. Skin and liversamples were fixed in 10% formalin embedded in paraffin and stained withhematoxylin and eosin and evaluated for ulcers, in the former andlymphocyte infiltration in the latter. Results were evaluated by X² andANOVA.

Assay for chimerism: Mice were anesthetized and blood taken from theretro-orbital sinus of she eye. WBC (2-8×10 ⁵/sample) were separated,directly stained with anti-H-2K^(b)-FITC (IgG_(2a)) oranti-H-2K^(d)-FITC (IgG_(2a)) monoclonal antibodies (mAb) (Serotec,USA), and analyzed by FACS analysis (FACStar plus, Becton Dickinson, SanJose, Calif., USA). Background binding of each H-2K-specific mAb wasdetermined by staining with it the cells of non-relevant haplotype.

GVHD Model experiment I. Following low-burden BMT, GVHD development, wasexamined following PIF-1 therapy (0.1-1 mg/kg/day) given for one weekusing an implanted Alzet® pump followed by one month observation. Of thePIF-1-treated mice, 0.1 or 1 mg/kg/day for one week, all eight mice didnot develop GVHD. Four out of five controls developed GVHD grade II-III(P<0.01). Mice following BMT and short term treatment remainedcompletely protected against the development of GVHD at one month aftercessation of therapy. In contrast, in control mice, severe skinulcerations and weight loss developed (mean mouse weight 21.9 g, highdose PIF-1 (N=3), 20.2 g low dose PIF-1 (N=5), and 19.5 g in controls).

GVHD Model experiment II (FIG. 1). We examined whether PIF-1 couldprevent GVHD development in a higher-burden BMT (double number of spleencells transplanted than the low-burden BMT). Following exposure to PIF-1(0.1-1 mg/kg/day) for two weeks, total protection against GVHD wasobtained within three weeks with die high dose therapy 7/7 vs. 9/9 incontrol with GVHD. This protection remained also significant (P<0.04) atthirty days post-BMT in both treatment groups, as evaluated by the GVHDscore in those which developed the disease (FIG. 2).

GVHD Model experiment III (FIG. 3). We examined whether short-termtreatment can lead to long term survival after cessation of therapy.Following high-burden BMT, PIF-1 1-5 mg/kg/day for two weeks wasadministered and mice were followed for an additional three and one-halfmonths without therapy. PIF-1 conferred a significant protection asdetermined by mouse survival at the end of the observation period. Sevenof nine of the PIF-1 treated mice survived compared to only two out often in controls (P<0.02). Higher-dose therapy was less effective,although it was still associated with a higher survival rate thancontrols (5/9 survived). Significant protection from weight loss wasalso achieved following PIF-1 1/mg/kg/day exposure vs. controls. Thiseffect became significant after day 33 from BMT. In control mice,following BMT, GVHD-induced skin ulcerations were observed. Short-termPIF-1 therapy presented the development of such lesions in the longterm. Liver histology also documented that lymphocytic infiltrates,indicating autoimmune response, were noted in control, but not inPIF-1-treated mice one month after cessation of therapy. The degree ofBMT incorporation into the recipient mice was determined. Results showthat there was a quasy total incorporation of grafted bone marrow afterfive weeks after BMT (87.5±2.4), reflected a very high degree ofchimerism.

Allo-BMT followed destruction of the host's immune system by total bodyradiation. Thereby the BMT recipient is highly vulnerable to immuneattack by the transplanted foreign immune cells. Low dose (micromolar)PIF-1 administration totally prevented GVHD while therapy wasadministered. More remarkably, long-term protection after cessation oftherapy was obtained, as reflected by the significant prevention of GVHDdevelopment and long-term survival for several months vs. control mice.This effect was not associated with any toxicity, as documented by mouseweight, skin appearance, and skin and liver histology. This was alsodocumented by the significant degree of chimerism (about 90%) thatdeveloped in the peripheral PBMC within live weeks following BMT,indicating that at that time the great majority of the mice immunesystem was constituted of the transplanted BM.

PIF-1's long-term protective effect after cessation of therapy isparticularly significant, as other BMT therapies are effective onlyduring active administration. Furthermore, the current BMT modelinvolved a clear mismatch between the recipient and the donor, and largequantities of cells were transplanted, while clinical settings useclosely matched BM donors, which nevertheless often, up to 70% resultsin various degrees of GVHD.

EXAMPLE 2

Materials and Methods are the Same as Example 1.

DM (adoptive transfer NOD) model. Male NOD mice were irradiated (650rad), and injected IV next day with 250 Mil spleen cells collected fromfemale NOD diabetic mice. PIF-1 was injected in two doses 0.83 mg/kg/day(N=5) and 2.73 mg/kg/day (N=7) for 28 days using an Alzet® pump,implanted subcutaneously providing continuous release of the peptide,followed by a 40-day observation period. Animals were monitored for DMdevelopment by determining lasting glucose levels in both blood andurine. Results were evaluated using ANOVA.

NOD diabetes model. We examined the effect of PIF-1 in a differentautoimmune model, NOD adoptive transfer. In this model, transfer ofdiabetic splenocytes from female to male mice leads progressively to thedevelopment of diabetes mellitus. Exposure to PIF-1 0.83-273 mg/kg/dayfor the first 28 days had a long-term protective effect against thedestruction of pancreatic cells and the consequent high serum glucoselevels. FIG. 4 shows a life table analysis of NOD mice followingadoptive transfer of splenocytes from a diabetic female mouse. By 70days, at the conclusion of the experiment, PIF-1 was totally protectivein 11/12 of mice treated with PIF-1 while 6/7 in the control group hasalready developed diabetes. Interestingly, the only PIF-1 treated mousethat developed DM received a higher treatment dose. The development ofdiabetes was documented by increased serum glucose levels; in certaincontrol animals it reached >600 mg/dl. Table 2, below, shows individualmice glucose levels after cessation of therapy.

TABLE 2 Non fasting blood Fasting blood NOD male glucose mg/dL glucosemg/dL mice No. (day 40) (day 69) Control 1 >600 355 2 >600 377 3 202 2324 193 5 >600 6 298 207 7 135 123 PIF 0.83 1 131 97 mg/kg/day 2 112 106 3137 119 4 132 109 5 130 149 PIF 2.73 1 118 87 mg/kg/day 2 126 108 3 125111 4 113 144 5 158 514 6 123 103 7 115 109

In the control group, most mice developed diabetes by 40 days.Additionally, histological examination demonstrated that PIF treatedmice were protected against inflammation of the pancreas v. control(data not shown) .

To further document PIF-1's immune-modulatory effects, we used the NODmouse adoptive transfer model, which results in the development ofdiabetes (rejected by high glucose levels) due to the destruction of therecipient's pancreas by transfer of autoreactive splenocytes from adiabetic mouse that targets specifically that organ. Using thisaggressive model, we documented a long-term protection against DMdevelopment using PIF-1 therapy. These results open the possibility ofexamining young adults that have recently developed DM in whom there hasnot been a total destruction of insulin-producing pancreas cells. Suchan early intervention could lead to a decreased need for insulinadministration, or even allow long-term oral anti-diabetic therapy.Since we found that PIF-1 targets isolated splenocytes that provides arationale for the protective effects that were observed. In TIDM primedT cells and macrophages directly attack the pancreas which is followedby local increase in T_(H)1 cytokines (i.e., TNF □,interferon-□) thatfurther amplify the auto-destructive process. PIF-1 may act on both ofthese aspects of autoimmunity by blocking activated immune cellsproliferation activation and modulating cytokines secretion, towards aT_(H)2 pattern (i.e., major increase in IL10).

EXAMPLE 3

Materials and Methods are the Same as Example 1.

MS EAE model: experimental autoimmune encephalomyelitis, SJL mice 7-8weeks old were injected in the tail base with 1:1 of 200 μg proteolyticprotein peptide (PLP) together with 200 μg CFA and IFA (containingmycobacterium tuberculosis). On the same day and two days later, micewere injected IP with 250 ng pertussis toxin. Within nine days, animalsstarted developing paralysis. PIF-1 was administered using asubcutaneously implanted Alzet® pump at 0.75 mg/kg/day for 28 days andits effect was compared to a control group. Daily monitoring of thedegree of paralysis (grade 0/no disease . . . 5/dead animal) occurred upto 40 days. PIF-1's protective effects were calculated using theMann-Whitney non parametric test.

MS model. We further examined whether PIF-1 therapy could be effectivein an additional autoimmune model, experimental autoimmuneencephalomyelitis (EAE) in which the majority of the damage occurs inpoorly accessible region of the body, the central nervous system. Byexposing mice to a combination of a toxic agent (PLP) for the nervoussystem together with boosting further the inflammatory response with twoadditional types of bacterial-toxins led to rapid paralysis <10 daysFIG. 5 shows that the exposure to PIF-1 at 0.75 mg/kg/day for 28 daysled to a continuous protection by significantly reducing the paralysisscore, as determined by daily observations using a clinical score. Theprotective effect also lasted tot at least two weeks after stoppingtherapy (P<0.002).

The experimental myeloencephalitis, EAE, is recognized as a highlyrelevant and acute model for MS. The exposure to auto-antigens coupledby induction with two bacterial immunogens leads to progressiveparalysis within short term. We found that PIF-1 led to a significant,reduction in the paralysis score across the observation period whichpersisted even two weeks after cessation of therapy. This is anindication that autoimmune neurological disorders may be alleviated byPIF-1. Additionally, histological examination demonstrated that PIFtreated mice were protected against inflammation of the spinal cord v.control (data not shown).

MS is believed to be the result of a genetic predisposition followed bya viral insult that leads to CD4+ autoreactive cells followed bydifferentiation to the T_(H)1 phenotype. On the other hand, local damageto central nervous system may occur by CD8+ T cells, and other elementsthat are involved in the innate immune system. This leads to alteredT_(H)2 cytokines, regulatory T, and NK cells and IFN□secretion. We havepreviously shown that several elements of this immune cascade aremodulated by PIF-1, consequently, the tolerogenic peptide may beinvolved in one or more aspects of this immune disorder.

EXAMPLE 4

To determine maximally tolerated dose of PIP-1 in patients who developGVHD after matched BMT, using an insulin pump. Recipients with grade IIGVHD will be randomized into three groups: (1) continue conventionaltherapy (i.e., steroids and cyclosporin A), as control; (2) add PIF-1therapy while continuing conventional therapy; and (3) stop conventionaltherapy and use PIF-1 alone. Patients will be continuously treated for 4weeks (using an insulin pump), with 30% dose increments, 15patients/group. Pre-therapy clinical indices, including tumor burden,will be compared to the same indices during/post -PIF-1 exposure,monitoring skin for lesions and testing organ function, including PBMCability to respond to mitogen challenge.

To examine PIF-1's effectiveness in GVHD prevention with maintainedanticancer effect. Upon successful completion of the first study, BMTrecipients will be randomized into three different groups: (1)conventional therapy (control); (2) conventional prophylaxis of GVHDcombined with PIF-1; (3) PIF-1 prophylaxis alone. At transplant,patients will begin PIF-1 therapy (using an insulin pump) at 30%increments for 12 weeks followed by 3+ months observation, 15patients/group. The number of patients that develop GVHD, the degree ofthe reaction, and response to cancer will be compared between the twotest groups.

EXAMPLE 5

Assess effect of PIF on PBMC isolated from patients with Chron'sdisease. Established patients PBMC (N=20) will be isolated and culturedin the presence of PIF alone using a dose dependent design and inpresence of +/− PHA, or CD3MAb/CD28Mab, used as mitogens, using Cloningmedia, serum free. After 24 hours of exposure PBMC culture media will becollected and tested for a) cytokine release, both TH1 and TH2, usingthe Luminex 10 package b) PIF receptor expression exposing to FITC-PIFand labeled-CD14, CD4, CD8, or CD58, or CD19MAb followed by flowcytometry) c) in selective cases, mRNA will be extracted and using anAffymetrix chip global genome analysis will be carried out. Results willbe compared with PBMC similarly treated derived from normal volunteers.

Assess effect of PIF on colon biopsy of patients with Chron's disease.In parallel, to obtaining PBMC also biopsies from the same patients willbe obtained during colonoscopy. Biopsy samples will be placed in cultureto generate explants using RPM11640 medium. Explant cultures will becarried out for 24 hours in the presence of PIF 0-200 nM. Subsequentlythe media will be collected and analyzed for cytokines using the 10multiplex Luminex system (TH1 and TH2). The tissue itself will be placedin formalin and will be analyzed for cytokine content using IHC, as wellas immune cell type presence using flow cytometry and specific CDmarkers.

Although the present invention has been described in considerable detailwith reference to certain preferred embodiments thereof, other versionsare possible. Therefore the spirit and scope of the appended claimsshould not be limited to the description and the preferred versionscontain within this specification.

1. A method of treating or preventing an immune-related disorder in asubject comprising administering a PIF peptide.
 2. The method of claim1, wherein said PIF peptide is selected from PIF-1₍₁₅₎ (SEQ ID NO: 13),PIF-2₍₁₃₎ (SEQ ID NO: 14), PIF-3₍₁₈₎ (SEQ ID NO: 15), PIF-1₍₉₎ (SEQ IDNO: 16),PIF-4₍₉₎ (SEQ ID NO: 17), PIF-1₍₅₎(SEQ ID NO: 18)andPIF-1₍₄₎(SEQ ID NO: 19).
 3. The method of claim 1, wherein said PIFpeptide is PIF-1₍₁₅₎ (SEQ ID NO: 13).
 4. The method of claim 1, whereina therapeutically effective amount of said PIF peptide is administered.5. The method of claim 4, wherein said therapeutically effective amountis from about 0.01 mg/kg to about 10 mg/kg.
 6. The method of claim 4,wherein said therapeutically effective amount is from about 0.1 mg/kg toabout 1.0 mg/kg.
 7. The method of claim 1 wherein said immune-relateddisorder is an auto-immune disorder selected from Hashimoto'sthyroiditis, pernicious anemia, Addison's disease, type I (insulindependent) diabetes, rheumatoid arthritis, systemic lupus erythematosus,dermatomyositis, Sjogren's syndrome, lupus erythematosus, multiplesclerosis, myasthenia gravis, Reiter's syndrome, and Grave's disease,alopecia areata, anklosing spondylitis, antiphospholipid syndrome,auto-immune hemolytic anemia, auto-immune- hepatitis, auto-immune innerear disease, auto-immune lymphoproliferative syndrome (ALPS),auto-immune thrombocytopenic purpura (ATP), Behcet's disease, bullouspemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatiguesyndrome immune deficiency syndrome (CFIDS), chronic inflammatorydemyelinating polyneuropathy, cicatricial pemphigoid, cold agglutinindisease, CREST syndrome, Crohn's disease, Dego's disease,dermatomyositis, dermatomyositis, discoid lupus, essential mixedcryoglobulinemia, fibromyalgia-fibromyositis, Guillain-Barre syndrome.idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura(ITP), IgA nephropathy, juvenile arthritis, Meniere's, mixed connectivetissue disease, pemphigus vulgaris, polyarteritis nodosa,polychondritis, polyglancular syndromes, polymyalgia rheumatica,polymyositis, primary agammaglobulinemia, primary biliary cirrhosis,psoriasis. Raynaud's phenomenon, rheumatic fever, sarcoidosis,scleroderma, stiff-man syndrome, Takayasu arteritis, temporalarteritis/giant cell arteritis, ulcerative colitis, uveitis, vasculitis,vitiligo, and Wegener's granulomatosis.
 8. The method of claim 1 whereinsaid immune-related disorder is graft-versus-host disease
 9. The methodof claim 1 wherein said immune-related disorder is type 1 (insulindependent) diabetes
 10. The method of claim 1 wherein saidimmune-related disorder is multiple sclerosis
 11. The method of claim 1wherein said immune-related disorder is Chron's disease
 12. The methodof claim 1 wherein said immune-related disorder is ulcerative colitis.